Yuda Zhu

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Nicholas E. Propson, R. Maciuca, K. Scearce-Levie, 2022, Science Translational Medicine.

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients

K. Scearce-Levie, M. Alonso-Alonso, P. D. De Deyn, 2022, Clinical and translational science.

Longitudinal biomarkers in amyotrophic lateral sclerosis

Robert H. Brown, K. Scearce-Levie, J. Glass, 2020, Annals of clinical and translational neurology.

Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients

K. Scearce-Levie, G. Astarita, M. Troyer, 2020, International journal of molecular sciences.

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome

T. Gill, K. Scearce-Levie, Elliot R. Thomsen, 2021, JCI insight.

DNL310 normalizes primary storage substrates and biomarkers of lysosomal dysfunction in neuronopathic MPS II: 2-year interim analysis of a phase 1/2 study

A. Bakardjiev, M. Troyer, Akhil Bhalla, 2023, Molecular Genetics and Metabolism.